Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
October 06, 2021 16:01 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting...
Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease
October 04, 2021 07:00 ET
|
Altimmune, Inc
First patient has been enrolled in 12-week non-alcoholic fatty liver disease (NAFLD) studyDr. Stephen Harrison will be serving as Principal Investigator for the studyTopline data readout expected in...
Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021
September 29, 2021 18:15 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on...
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
September 28, 2021 07:01 ET
|
Altimmune, Inc
Mean weight loss of 10.3% achieved in subjects receiving 1.8 mg dosePemvidutide was well-tolerated without the need for dose titration No discontinuations due to treatment-emergent adverse eventsNASH...
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
September 27, 2021 16:01 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week...
Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
September 07, 2021 16:01 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present...